Archives: Speakers

Aimee Hogue is Director of Supply Chain at Sutro Biopharma, where she leads global clinical supply strategy, CMO/CDMO management, and end-to-end supply planning for oncology development programs and strategic partnerships. With more than 20 years of biopharmaceutical experience spanning research, development, manufacturing, and clinical supply, Aimee has overseen technology transfers, production scheduling, cold-chain distribution, and clinical supply operations across a global network of manufacturing partners. She has developed CDMO evaluation frameworks, led Joint Steering Committees, and driven vendor performance management to ensure flexibility, reliability, and scalability from early-stage development through Phase 3 clinical trials.

Sandra Bekerman is Co-Founder and CEO of Adnexi, whose direct-to-patient enrollment and patient advocacy platforms are used by leading biopharma companies and CROs. Previously she founded Seeker Health, a digital patient-finding platform acquired by EVERSANA in 2018, and held biopharma roles at BioMarin, Nora Therapeutics, Johnson & Johnson and Genentech. She is the author of New Startup Mindset and holds an MBA from Wharton.

Coby Shpilberg is Co-Founder and CTO of Adnexi, where he built the platform now in use by leaeding biopharma companies and CROs. His work covers the technology behind Adnexi’s direct-to-patient campaigns, the patient pre-screening and referral portal used by sponsors and sites, and the global patient advocacy group platform. Outside of technology for clinical trials, he is a former Team USA Junior National athlete in luge. He studied Computer Science at the University of Michigan.

Burkard Kolb has 22 years of experience in the development and manufacture of biologics. Starting out at Roche Penzberg,  Singapore and at Genentech in South San Francisco, he focused on internal development and manufacturing projects in Engineering and MSAT positions. During his tenure at Coherus Oncology and 89bio, he managed external manufacturing of Drug Substance for biosimilars and novel biologic drugs, handling site selection, tech transfer, process characterization and validation activities. He has been an author of CMC sections for multiple successful BLA and IND submissions.